Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Mo, Xiao-Dong  [Clear All Filters]
2020
Zeng, Q.-Z., Zhang, Y.-Y., Wu, Y.-J., Zhang, Z.-Y., Zhang, J.-N., Fu, H.-X., Wang, J.-Z., Wang, F.-R., Yan, C.-H., Mo, X.-D., et al. (2020). Frequency, risk factors and outcome of active tuberculosis following allogeneic hematopoietic stem cell transplantation.Biol Blood Marrow Transplant.
Liu, J., Gao, H., Xu, L.-P., Mo, X.-D., Liu, R., Liang, S., Wu, N., Wang, M., Wang, Z., Chang, Y.-J., et al. (2020). Immunosuppressant indulges EBV reactivation and related lymphoproliferative disease by inhibiting Vδ2 T cells activities after hematopoietic transplantation for blood malignancies.J Immunother Cancer8.
Tang, F.-F., Sun, Y.-Q., Mo, X.-D., Lv, M., Chen, Y.-H., Wang, Y., Xu, L.-P., Zhang, X.-H., and Huang, X.-J. (2020). The incidence, risk factors, and outcomes of primary prolonged isolated thrombocytopenia after haploidentical hematopoietic stem cell transplantation.Biol Blood Marrow Transplant.
Chen, Q., Zhao, X., Fu, H.-X., Chen, Y.-H., Zhang, Y.-Y., Wang, J.-Z., Wang, Y., Wang, F.-R., Mo, X.-D., Han, W., et al. (2020). Posterior reversible encephalopathy syndrome (PRES) after haploidentical haematopoietic stem cell transplantation: incidence, risk factors and outcomes.Bone Marrow Transplant.
Liu, S.-N., Zhang, X.-H., Xu, L.-P., Wang, Y., Yan, C.-H., Chen, H., Chen, Y.-H., Han, W., Wang, F.-R., Wang, J.-Z., et al. (2020). Prognostic factors and long-term follow-up of basiliximab for steroid-refractory acute GVHD: updated experienced from a large-scale study.Am J Hematol.
Chang, Y.-J., Xu, L.-P., Wang, Y., Zhang, X.-H., Chen, H., Chen, Y.-H., Wang, F.-R., Han, W., Sun, Y.-Q., Yan, C.-H., et al. (2020). Rituximab for desensitization during HLA-mismatched stem cell transplantation in patients with a positive donor-specific anti-HLA antibody.Bone Marrow Transplant.
2019
Mo, X.-D., Zhang, X.-H., Xu, L.-P., Wang, Y., Yan, C.-H., Chen, H., Chen, Y.-H., Han, W., Wang, F.-R., Wang, J.-Z., et al. (2019). Corrigendum to 'Interferon α: A potentially effective treatment for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation' [Biology of Blood and Marrow Transplantation 21/11 (2015) 19.Biol Blood Marrow Transplant.
Mo, X.-D., Zhang, X.-H., Xu, L.-P., Wang, Y., Yan, C.-H., Chen, H., Chen, Y.-H., Han, W., Wang, F.-R., Wang, J.-Z., et al. (2019). Corrigendum to 'Interferon-α is effective for treatment of minimal residual disease in patients with acute leukemia after allogeneic hematopoietic stem cell transplantation: results of a registry study' [Biology of Blood and Marrow Transplantation 23/8 (.Biol Blood Marrow Transplant.
Zhang, Y.-Y., Mo, X.-D., Zhang, X.-H., Xu, L.-P., Wang, Y., Yan, C.-H., Chen, H., Chen, Y.-H., Han, W., Wang, F.-R., et al. (2019). FLT3 internal tandem duplication does not impact prognosis after haploidentical allogeneic hematopoietic stem cell transplantation in AML patients.Bone Marrow Transplant.
Wang, X.-L., Han, W., Zhao, P., Liu, X., Wang, J.-Z., Wang, F.-R., Yan, C.-H., Zhang, Y.-Y., Mo, X.-D., Wang, Y., et al. (2019). Incidence, Risk Factors, Outcomes and Risk Score Model of Acute Pancreatitis after Allogeneic Hematopoietic Stem Cell Transplantation.Biol Blood Marrow Transplant.
Wang, X.-Y., Fan, Q.-Z., Xu, L.-P., Wang, Y., Zhang, X.-H., Chen, H., Chen, Y.-H., Wang, F.-R., Han, W., Sun, Y.-Q., et al. (2019). The Quantification of Minimal Residual Disease Pre- and Post-Unmanipulated Haploidentical Allograft by Multiparameter Flow Cytometry in Pediatric Acute Lymphoblastic Leukemia.Cytometry B Clin Cytom.